| pubmed-article:65838 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:65838 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:65838 | lifeskim:mentions | umls-concept:C0341628 | lld:lifeskim |
| pubmed-article:65838 | lifeskim:mentions | umls-concept:C0268731 | lld:lifeskim |
| pubmed-article:65838 | lifeskim:mentions | umls-concept:C0002198 | lld:lifeskim |
| pubmed-article:65838 | lifeskim:mentions | umls-concept:C1412046 | lld:lifeskim |
| pubmed-article:65838 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:65838 | pubmed:dateCreated | 1977-4-25 | lld:pubmed |
| pubmed-article:65838 | pubmed:abstractText | The serum and urine levels of alpha-2-macroglobulin (alpha2-MG) was determined in 33 children with glomerular diseases and in 26 healthy control children. Healthy children showed a minimum level of 275 mg% and maximum level of 337 mg%, with a mean concentration of 301 mg% and a standard deviation of 13 mg%. No alpha2-MG was detected in the urine. Steroid-treated patients with idiopathic nephrotic syndrome displayed elevated inhibitor levels of up to 490 mg%. This might be a direct result of steroid therapy or a consequence of reactively-increased protein synthesis in response to the renal protein loss. In all these patients the urine was found to be alpha2-MG-negative, irrespective of the presence or absence of proteinuria. In the miscellaneous group of glomerulopathies without the nephrotic syndrome, serum levels of alpha2-MG were shown to be normal. The urinary concentrations of alpha2-MG were related to the activity of the disease. alpha2-MG determination in serum and urine seems to be a tool for differential diagnosis and prognosis in some cases of glomerular disease. | lld:pubmed |
| pubmed-article:65838 | pubmed:language | ger | lld:pubmed |
| pubmed-article:65838 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:65838 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:65838 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:65838 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:65838 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:65838 | pubmed:issn | 0043-5325 | lld:pubmed |
| pubmed-article:65838 | pubmed:author | pubmed-author:Weissenbacher... | lld:pubmed |
| pubmed-article:65838 | pubmed:author | pubmed-author:BalzarEE | lld:pubmed |
| pubmed-article:65838 | pubmed:author | pubmed-author:LubecGG | lld:pubmed |
| pubmed-article:65838 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:65838 | pubmed:day | 21 | lld:pubmed |
| pubmed-article:65838 | pubmed:volume | 89 | lld:pubmed |
| pubmed-article:65838 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:65838 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:65838 | pubmed:pagination | 49-53 | lld:pubmed |
| pubmed-article:65838 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:65838 | pubmed:meshHeading | pubmed-meshheading:65838-Hu... | lld:pubmed |
| pubmed-article:65838 | pubmed:meshHeading | pubmed-meshheading:65838-Ad... | lld:pubmed |
| pubmed-article:65838 | pubmed:meshHeading | pubmed-meshheading:65838-Ch... | lld:pubmed |
| pubmed-article:65838 | pubmed:meshHeading | pubmed-meshheading:65838-Di... | lld:pubmed |
| pubmed-article:65838 | pubmed:meshHeading | pubmed-meshheading:65838-Ki... | lld:pubmed |
| pubmed-article:65838 | pubmed:meshHeading | pubmed-meshheading:65838-Ch... | lld:pubmed |
| pubmed-article:65838 | pubmed:meshHeading | pubmed-meshheading:65838-Pr... | lld:pubmed |
| pubmed-article:65838 | pubmed:meshHeading | pubmed-meshheading:65838-Fe... | lld:pubmed |
| pubmed-article:65838 | pubmed:meshHeading | pubmed-meshheading:65838-Ma... | lld:pubmed |
| pubmed-article:65838 | pubmed:meshHeading | pubmed-meshheading:65838-Gl... | lld:pubmed |
| pubmed-article:65838 | pubmed:meshHeading | pubmed-meshheading:65838-Ne... | lld:pubmed |
| pubmed-article:65838 | pubmed:meshHeading | pubmed-meshheading:65838-Cl... | lld:pubmed |
| pubmed-article:65838 | pubmed:meshHeading | pubmed-meshheading:65838-Ac... | lld:pubmed |
| pubmed-article:65838 | pubmed:meshHeading | pubmed-meshheading:65838-Ne... | lld:pubmed |
| pubmed-article:65838 | pubmed:meshHeading | pubmed-meshheading:65838-al... | lld:pubmed |
| pubmed-article:65838 | pubmed:year | 1977 | lld:pubmed |
| pubmed-article:65838 | pubmed:articleTitle | [Alpha-2-macroglobulin in children with glomerular diseases (author's transl)]. | lld:pubmed |
| pubmed-article:65838 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:65838 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:65838 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:65838 | pubmed:publicationType | English Abstract | lld:pubmed |
